Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter studyFumihiko Urabe, Takahiro Kimura, Tatsuya Shimomura et al.|Japanese Journal of Clinical Oncology|2024Cited by 22
Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter studyFumihiko Urabe, Takahiro Kimura, Kojiro Tashiro et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 11
Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective studyShuhei Hara, Takahiro Kimura, Keiichiro Mori et al.|International Journal of Clinical Oncology|2024Cited by 9
Stage <scp>III</scp> substaging and outcomes in patients with bladder cancer undergoing radical cystectomyShuhei Hara, Wataru Fukuokaya, Jun Miki et al.|International Journal of Urology|2025Cited by 7
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Takahiro Kimura, Hirokazu Kagawa et al.|Prostate International|2024Cited by 6